Picture loading failed.

Anti-IL3RA;CD3E therapeutic antibody (Pre-made Vibecotamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vibecotamab (XmAb?14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-619-1mg 1mg 3090
GMP-Bios-ab-619-10mg 10mg 21890
GMP-Bios-ab-619-100mg 100mg 148000
GMP-Bios-ab-619-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL3RA;CD3E therapeutic antibody (Pre-made Vibecotamab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Vibecotamab
TargetIL3RA;CD3E
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2018
Year Recommended2019
CompaniesXencor
Conditions Approvedna
Conditions ActiveHaematological malignancies
Conditions Discontinuedna
Development Techna